secwatch.observer — SEC 8-K summary
======================================

Issuer:     Third Harmonic Bio, Inc. (—)
CIK:        0001923840
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036162
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Third Harmonic Bio reports $269.1M cash, files IND for THB335, Q4 net loss narrows
--------------------------------------------------------------------------------

- Cash and equivalents $269.1M as of Dec 31, 2023; expected to fund operations through at least 2026.
- Net loss for Q4 2023 was $6.8M versus $11.5M in Q4 2022; full-year net loss $30.8M.
- R&D expenses decreased to $5.9M in Q4 2023 from $9.3M year-over-year.
- U.S. IND filed for THB335, a potential first-in-class oral KIT inhibitor for chronic spontaneous urticaria.
- Phase 1 SAD/14-day MAD study in healthy volunteers anticipated to start in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/0000950170-24-036162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1923840/000095017024036162/thrd-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer